Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16203704 | 0.80 | ALDH1A1 (0.35) | KMT2AATMMGLLALDH1A1POLB | |
| SCHEMBL73278 | 0.80 | KMT2A (0.47) | KMT2AATMMGLLALDH1A1 | |
| SCHEMBL865136 | 0.79 | MGLL (0.40) | KMT2AATMMGLL | |
| SCHEMBL28964134 | 0.78 | MGLL (0.36) | KMT2AATMMGLL | |
| SCHEMBL17550003 | 0.77 | KMT2A (0.38) | KMT2AATMMGLL | |
| SCHEMBL28291959 | 0.76 | MGLL (0.35) | KMT2AATMMGLL | |
| SCHEMBL19447119 | 0.76 | KMT2A (0.34) | KMT2AATMMGLL | |
| Methacrylic Acid SCHEMBL27191395 | 0.76 | KMT2A (0.44) | KMT2AATMMGLLALDH1A1 | |
| SCHEMBL10889616 | 0.75 | GLA (0.39) | KMT2AATMMGLLPOLB | |
| SCHEMBL756450 | 0.75 | MGLL (0.36) | KMT2AATMMGLLALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172400-A1 | COMPOSITIONS MONOVALENT FOR CD40L BINDING AND METHODS OF USE | DOMANTIS LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172400-A1 | COMPOSITIONS MONOVALENT FOR CD40L BINDING AND METHODS OF USE | CD40LG, CD40, CD4 | KMT2A 3810/4885ATM 4267/4885MGLL 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.